CNTRL
Centriolin
Also known as: CEP1, CEP110, CNTRL_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q7Z7A1
- Gene
- CNTRL
- Ensembl
- ENSG00000119397
- Chromosome
- 9
- Canonical length
- 2325 aa
- Protein class
- Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins
- Subcellular location
- Golgi apparatus,Plasma membrane,Centriolar satellite,Centrosome,Basal body,Cytosol,Flagellar centriole
OverviewNCBI Gene
This gene encodes a centrosomal protein required for the centrosome to function as a microtubule organizing center. The gene product is also associated with centrosome maturation. One version of stem cell myeloproliferative disorder is the result of a reciprocal translocation between chromosomes 8 and 9, with the breakpoint associated with fibroblast growth factor receptor 1 and centrosomal protein 1. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
2325 residues, UniProt reviewed canonical sequence.
>Q7Z7A1|CNTRL
1 MKKGSQQKIF SKAKIPSSSH SPIPSSMSNM RSRSLSPLIG SETLPFHSGG QWCEQVEIAD
61 ENNMLLDYQD HKGADSHAGV RYITEALIKK LTKQDNLALI KSLNLSLSKD GGKKFKYIEN
121 LEKCVKLEVL NLSYNLIGKI EKLDKLLKLR ELNLSYNKIS KIEGIENMCN LQKLNLAGNE
181 IEHIPVWLGK KLKSLRVLNL KGNKISSLQD ISKLKPLQDL ISLILVENPV VTLPHYLQFT
241 IFHLRSLESL EGQPVTTQDR QEAFERFSLE EVERLERDLE KKMIETEELK SKQTRFLEEI
301 KNQDKLNKSL KEEAMLQKQS CEELKSDLNT KNELLKQKTI ELTRACQKQY ELEQELAFYK
361 IDAKFEPLNY YPSEYAEIDK APDESPYIGK SRYKRNMFAT ESYIIDSAQA VQIKKMEPDE
421 QLRNDHMNLR GHTPLDTQLE DKEKKISAAQ TRLSELHDEI EKAEQQILRA TEEFKQLEEA
481 IQLKKISEAG KDLLYKQLSG RLQLVNKLRQ EALDLELQME KQKQEIAGKQ KEIKDLQIAI
541 DSLDSKDPKH SHMKAQKSGK EQQLDIMNKQ YQQLESRLDE ILSRIAKETE EIKDLEEQLT
601 EGQIAANEAL KKDLEGVISG LQEYLGTIKG QATQAQNECR KLRDEKETLL QRLTEVEQER
661 DQLEIVAMDA ENMRKELAEL ESALQEQHEV NASLQQTQGD LSAYEAELEA RLNLRDAEAN
721 QLKEELEKVT RLTQLEQSAL QAELEKERQA LKNALGKAQF SEEKEQENSE LHAKLKHLQD
781 DNNLLKQQLK DFQNHLNHVV DGLVRPEEVA ARVDELRRKL KLGTGEMNIH SPSDVLGKSL
841 ADLQKQFSEI LARSKWERDE AQVRERKLQE EMALQQEKLA TGQEEFRQAC ERALEARMNF
901 DKRQHEARIQ QMENEIHYLQ ENLKSMEEIQ GLTDLQLQEA DEEKERILAQ LRELEKKKKL
961 EDAKSQEQVF GLDKELKKLK KAVATSDKLA TAELTIAKDQ LKSLHGTVMK INQERAEELQ
1021 EAERFSRKAA QAARDLTRAE AEIELLQNLL RQKGEQFRLE MEKTGVGTGA NSQVLEIEKL
1081 NETMERQRTE IARLQNVLDL TGSDNKGGFE NVLEEIAELR REVSYQNDYI SSMADPFKRR
1141 GYWYFMPPPP SSKVSSHSSQ ATKDSGVGLK YSASTPVRKP RPGQQDGKEG SQPPPASGYW
1201 VYSPIRSGLH KLFPSRDADS GGDSQEESEL DDQEEPPFVP PPGYMMYTVL PDGSPVPQGM
1261 ALYAPPPPLP NNSRPLTPGT VVYGPPPAGA PMVYGPPPPN FSIPFIPMGV LHCNVPEHHN
1321 LENEVSRLED IMQHLKSKKR EERWMRASKR QSEKEMEELH HNIDDLLQEK KSLECEVEEL
1381 HRTVQKRQQQ KDFIDGNVES LMTELEIEKS LKHHEDIVDE IECIEKTLLK RRSELREADR
1441 LLAEAESELS CTKEKTKNAV EKFTDAKRSL LQTESDAEEL ERRAQETAVN LVKADQQLRS
1501 LQADAKDLEQ HKIKQEEILK EINKIVAAKD SDFQCLSKKK EKLTEELQKL QKDIEMAERN
1561 EDHHLQVLKE SEVLLQAKRA ELEKLKSQVT SQQQEMAVLD RQLGHKKEEL HLLQGSMVQA
1621 KADLQEALRL GETEVTEKCN HIREVKSLLE ELSFQKGELN VQISERKTQL TLIKQEIEKE
1681 EENLQVVLRQ MSKHKTELKN ILDMLQLENH ELQGLKLQHD QRVSELEKTQ VAVLEEKLEL
1741 ENLQQISQQQ KGEIEWQKQL LERDKREIER MTAESRALQS CVECLSKEKE DLQEKCDIWE
1801 KKLAQTKRVL AAAEENSKME QSNLEKLELN VRKLQQELDQ LNRDKLSLHN DISAMQQQLQ
1861 EKREAVNSLQ EELANVQDHL NLAKQDLLHT TKHQDVLLSE QTRLQKDISE WANRFEDCQK
1921 EEETKQQQLQ VLQNEIEENK LKLVQQEMMF QRLQKERESE ESKLETSKVT LKEQQHQLEK
1981 ELTDQKSKLD QVLSKVLAAE ERVRTLQEEE RWCESLEKTL SQTKRQLSER EQQLVEKSGE
2041 LLALQKEADS MRADFSLLRN QFLTERKKAE KQVASLKEAL KIQRSQLEKN LLEQKQENSC
2101 IQKEMATIEL VAQDNHERAR RLMKELNQMQ YEYTELKKQM ANQKDLERRQ MEISDAMRTL
2161 KSEVKDEIRT SLKNLNQFLP ELPADLEAIL ERNENLEGEL ESLKENLPFT MNEGPFEEKL
2221 NFSQVHIMDE HWRGEALREK LRHREDRLKA QLRHCMSKQA EVLIKGKRQT EGTLHSLRRQ
2281 VDALGELVTS TSADSASSPS LSQLESSLTE DSQLGQNQEK NASARLocalizationUniProt · AlphaFold · HPA
Whether an antibody against CNTRL can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.47
- Highest tissue expression
- 28 nTPM
Expression across tissuesHPA
Tissue
- testis: 28 nTPM
- lymph node: 20 nTPM
- thymus: 19 nTPM
- tonsil: 18 nTPM
- bone marrow: 16 nTPM
- appendix: 11 nTPM
Single-cell type
- monocyte progenitors: 414 nCPM
- early primary spermatocytes: 406 nCPM
- late primary spermatocytes: 402 nCPM
- neutrophil progenitors: 332 nCPM
- respiratory ciliated cells: 316 nCPM
- fallopian tube ciliated cells: 258 nCPM
Immune cell
- eosinophil: 7.5 nTPM
- memory B-cell: 6.7 nTPM
- basophil: 6 nTPM
- naive B-cell: 6 nTPM
- T-reg: 5.7 nTPM
- naive CD4 T-cell: 5.3 nTPM
Brain region
- choroid plexus: 16 nTPM
- cerebellum: 15 nTPM
- medulla oblongata: 15 nTPM
- white matter: 14 nTPM
- hypothalamus: 14 nTPM
- midbrain: 14 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about CNTRL.
Disease | AutoantibodyPubMed
Conditions in which antibodies against CNTRL are reported. Each links to that disease's full target list.
ReferencesPubMed · IEDB
Publications for CNTRL from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
15 publications
- Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis.
2013 · Arthritis Rheum · RCR 5.3 · 161 citations - Synovial fluid is a site of citrullination of autoantigens in inflammatory arthritis.
2008 · Arthritis Rheum · RCR 4.9 · 196 citations - Association of Distinct Fine Specificities of Anti-Citrullinated Peptide Antibodies With Elevated Immune Responses to Prevotella intermedia in a Subgroup of Patients With Rheumatoid Arthritis and Periodontitis.
2017 · Arthritis Rheumatol · RCR 2.1 · 47 citations - Anti-citrullinated alpha enolase antibodies, interstitial lung disease and bone erosion in rheumatoid arthritis.
2018 · Rheumatology (Oxford) · RCR 1.8 · 33 citations - Associations of antibodies against citrullinated peptides with human leukocyte antigen-shared epitope and smoking prior to the development of rheumatoid arthritis.
2015 · Arthritis Res Ther · RCR 1.6 · 45 citations
Show 10 more
- Association of levels of antibodies against citrullinated cyclic peptides and citrullinated α-enolase in chronic and aggressive periodontitis as a risk factor of Rheumatoid arthritis: a case control study.
2015 · J Transl Med · RCR 1.2 · 25 citations - Antibodies to citrullinated α-enolase peptide 1 and clinical and radiological outcomes in rheumatoid arthritis.
2011 · Ann Rheum Dis · RCR 1.2 · 38 citations - Particular association of clinical and genetic features with autoimmunity to citrullinated α-enolase in rheumatoid arthritis.
2011 · Arthritis Rheum · RCR 0.9 · 33 citations - Antibodies against citrullinated alpha enolase peptides in primary Sjogren's syndrome.
2017 · Clin Immunol · RCR 0.7 · 14 citations - Is periodontitis a prognostic factor in order to indicate antibodies against citrullinated peptides in patients with rheumatoid arthritis?
2020 · Clin Exp Rheumatol · RCR 0.6 · 9 citations - Diagnostic value of anti-citrullinated α-enolase peptide 1 antibody in patients with rheumatoid arthritis: A systematic review and meta-analysis.
2021 · Int J Rheum Dis · RCR 0.6 · 7 citations - Anti-citrullinated glucose-6-phosphate isomerase peptide antibodies in patients with rheumatoid arthritis are associated with HLA-DRB1 shared epitope alleles and disease activity.
2013 · Clin Exp Immunol · RCR 0.5 · 15 citations - The value of neutrophil gelatinase-associated lipocalin and citrullinated alpha enolase peptide-1 antibody in diagnosis, classification, and prognosis for patients with sepsis.
2020 · Medicine (Baltimore) · RCR 0.4 · 5 citations - Association between anti-citrullinated alpha enolase antibodies and clinical features in a cohort of patients with rheumatoid arthritis: a pilot study.
2018 · Reumatismo · RCR 0.2 · 4 citations - Evaluation of the Value of Anti-Citrullinated α-enolase Peptide 1 Antibody in the Diagnosis of Rheumatoid Arthritis.
2019 · Ann Clin Lab Sci · RCR 0.2 · 3 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.89
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.22
- DepMap mean gene effect
- -0.03
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- aorta development
- cell division
- coronary vasculature development
- kidney development
- ventricular septum development
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of CNTRL in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads CNTRL as an antibody target. Whether an autoantibody or antibody against CNTRL could matter depends on whether native CNTRL is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
CNTRL is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label CNTRL as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...